- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02545478
Biomarkers in Infection
Early Detection of Inflammatory Biomarkers in Infection
Přehled studie
Detailní popis
The body's immune system and a subsequent inflammatory response are triggered during infection. The detection of an activated immune system, and an indication of the degree of the host response, is helpful to the clinician both in assessing the severity of infection and in patient treatment and management. Currently, the white blood cell count and the differential are the most common laboratory parameters for measuring host response. The sedimentation rate and CRP are also used to detect inflammation. However, these tests are all imperfect predictors, and a test providing a better assessment of immune response would be helpful to the clinician in patient care. Additionally, understanding host response to infection may be helpful in understanding the biology and pathophysiology of sepsis. There are other biomarkers and inflammatory markers that may be found early in the initial presentation of infection such as cytokines (VEGF IL-1,IL-4,IL-6, IL-10, PAF, TNF, lectins iNoS,etc.) and clotting factors (protein C, d-dimer, complements involved in the clotting cascade, CRP, etc) that may provide a means of early detection of systemic inflammation, cell dysfunction, and related conditions. Early identification of patients at risk for systemic inflammatory syndromes, sepsis and septic shock may help direct patients to earlier antibiotic administration and early intervention with goal directed therapy. It may also serve as a tool for risk stratification when components such as age, comorbid illness and infection type are included.
The endothelium and endothelial cell markers are important in sepsis, yet a somewhat under-studied field of research. Additionally, the endothelium is a key regulator of the microcirculation, a place where oxygen diffusion occurs. One focus of this study is to measure endothelial markers (ie VEGF) and other cytokines with the goal of correlating these markers with severity of sepsis. Another focus is to study the response of various components in the blood, including the leukocytes, red cells, the endothelium, as well as cellular components such as the mitochondria. We will specifically look at alterations in thiamine, Vitamin D, CoQ10,l-carnitine and other nutrients as part of (and as related to) the body's response. Recently, a non-invasive method of assessing microvascular circulation by orthogonal polarization spectral (OPS) imagery has become available using a non-invasive technology known as orthogonal polarization spectroscopy. This technique enables direct visualization and quantification of microcirculatory blood flow, and represents an important surrogate outcome to which endothelial cell marker may be correlated. This will involve placing the microscopy probe gently against the sublingual mucosa and collecting a videotape of the circulation lasting about twenty seconds. This process involves minimal (or no) risk - it is akin to taking a temperature and uses no radiation. This videotape will be examined later by a novel software program that quantifies the circulation and used as an important surrogate outcome measure. Additionally, we are going to perform echocardiography to better understand the heart's response to sepsis, and correlated the molecular responses that we find with the changes in the responses by the heart.
This is a multicenter, observational pilot study which aims to evaluate how early biomarkers of infection an inflammation perform in identifying patients at risk for poor outcomes in sepsis and septic shock. The study will utilize a cohort of patients presenting to the ED with suspected infection as well as non-infected control population.
These patients will be compared with a non-infected population.
Enrolled subjects in the infected group will have blood samples and chart review obtained at enrollment, 24, 48 and 72 hours. For the control group, only a single blood draw will be collected at enrollment.
Enrolled subjects will also undergo physiologic assessments using echocardiography, Microscan, Non-invasive cardiac output monitor (NICOM), extremity temperature as well as End-Tidal C02 measurements if a trained researcher is present.
Typ studie
Zápis (Očekávaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Nathan Shapiro, MD MPH
- Telefonní číslo: 617-754-2343
- E-mail: nshapiro@bidmc.harvard.edu
Studijní záloha kontaktů
- Jméno: Sharon R Hayes, RN
- Telefonní číslo: 617-754-2334
- E-mail: srhayes@bidmc.harvard.edu
Studijní místa
-
-
-
Aarhus, Dánsko
- Zatím nenabíráme
- Aarhus Universitetshospital
-
Kontakt:
- Hans Kirkegaard
- E-mail: Hans Kirkegaard <hanskirkegaard@dadlnet.dk>
-
Vrchní vyšetřovatel:
- Hans Kirkegaard, MD
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Nábor
- Beth Israel Deaconess Medical Center
-
Kontakt:
- Nathan Shapiro, MD MPH
- Telefonní číslo: 617-754-2343
- E-mail: nshapiro@bidmc.harvard.edu
-
Boston, Massachusetts, Spojené státy, 02114
- Aktivní, ne nábor
- Massachusetts General Hospital
-
Boston, Massachusetts, Spojené státy, 02215
- Aktivní, ne nábor
- Brigham and Women's Hospital
-
Worcester, Massachusetts, Spojené státy, 01608
- Nábor
- St. Vincent's Hospital
-
Kontakt:
- David Miru, RN
- Telefonní číslo: 508-363-5286
- E-mail: dmiru@bidmc.harvard.edu
-
Kontakt:
- Pamel Sigel, RN
- Telefonní číslo: 508-363-7018
- E-mail: PAMELA.SIGEL@stvincenthospital.com
-
Vrchní vyšetřovatel:
- Nathan Shapiro, MD MPH
-
-
New York
-
Brooklyn, New York, Spojené státy, 11215
- Nábor
- New York Methodist Hospital
-
Kontakt:
- Robert Birkhahn, MD
-
Vrchní vyšetřovatel:
- Rorber Birkhahn, MD
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37232
- Nábor
- Vanderbiltt University
-
Kontakt:
- Wesley Self, MD
- Telefonní číslo: 615-936-0253
- E-mail: wesley.self@vanderbilt.edu
-
Vrchní vyšetřovatel:
- Wesley Self, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria for Infected subjects:
- Age 18 years of age or older
- Confirmed or suspected infection
Inclusion Criteria for Control Subjects:
- Age 18 years of age or older
- A non-infectious clinical presentation to include
- Normal white blood cell count ( > 4,000 and/or < 12,000)
- Normothermia ( > 96.5 and/or less 100.4)
- Absence of the following clinical complaints: productive cough, fever, pyuria, rash
- No evidence of acute coronary syndrome
Exclusion Criteria for Control Subjects:
- Suspected infection
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
---|
Infected Group
subjects with suspected infection
|
Non-infected group
subjects without any infection
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
28 day in-hospital mortality
Časové okno: within 28 days after inclusion
|
participants will be followed up for 28 days
|
within 28 days after inclusion
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Organ Dysfunction assessed by Sepsis-related Organ Failure Assessment (SOFA) Score
Časové okno: within 24 hours
|
within 24 hours
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Nathan Shapiro, MD MPH, Beth Israel Deaconess Medical Center
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2005P000116
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Sepse
-
Drugs for Neglected DiseasesUniversiteit Antwerpen; PENTA Foundation; St George's, University of LondonDokončenoNovorozenecká SEPSISBangladéš, Uganda, Thajsko, Jižní Afrika, Itálie, Řecko, Indie, Brazílie, Čína, Keňa, Vietnam
-
Assiut UniversityNeznámýNovorozenecká SEPSIS
-
Assiut UniversityNeznámý
-
London School of Hygiene and Tropical MedicineDokončenoNovorozenecká SEPSISBurkina Faso, Gambie
-
Stephanie BjerrumRigshospitalet, Denmark; University of Copenhagen; University of Ghana; Korle-Bu...DokončenoNovorozenecká SEPSISGhana
-
Drugs for Neglected DiseasesUniversity of Oxford; KEMRI-Wellcome Trust Collaborative Research ProgramDokončenoNovorozenecká SEPSISKeňa
-
Gehad AbdelnaserAssiut UniversityNeznámý
-
Assiut UniversityNeznámý
-
Franciscus GasthuisErasmus Medical CenterDokončenoNovorozenecká infekce | Novorozenecká SEPSISHolandsko
-
Ahmed Mahmoud Ali Ali YoussefDokončenoNovorozenecká SEPSISEgypt